Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New 3D-Printed swabs could ease COVID test shortages

NCT ID NCT07469670

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study checked whether 3D-printed nasal swabs work as well as standard swabs for diagnosing COVID-19. About 1,179 people who had COVID-19 symptoms or were recently exposed took part. Researchers compared the new swabs' accuracy and safety, like nosebleed risk, to the usual ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,179 people

The number who actually took part.

Started

Apr 2021

Finished

Aug 2022

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Employees and patients with recent (\<2 weeks) COVID-19 diagnosis for themselves or a member of their home, or who are symptomatic with one or more COVID-19 symptoms are eligible.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic or COVID-19 positive (within the past 2 weeks) * Has a COVID-19 positive household member * Female and male Veterans or female and male VHA employees * Able and willing to give informed consent Exclusion Criteria: * Self-reported history of frequent nosebleeds or a diagnosis of coagulopathy or any bleeding disorders * Unsuitability for mid-turbinate or nasopharyngeal swabbing due to prior surgery * Need for legally authorized representative for purpose of giving consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington, 98108-1532, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.